User login
Key clinical point: Long-term abrocitinib monotherapy or with medicated topical therapy demonstrates a manageable safety profile and significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults and adolescents.
Major finding: At week 48, in the 200 and 100 mg abrocitinib groups, Eczema Area and Severity Index-75 (EASI 75) responses and ≥4-point improvements in Peak Pruritus Numerical Rating Scale (PP-NRS) scores were achieved by 81.7% and 66.8% (EASI 75), and 67.9% and 51.1% (PP-NRS) of patients, respectively; serious treatment-emergent adverse event rates were 7.1% and 4.7% (200 mg vs 100 mg), respectively.
Study details: This phase 3 long-term extension study JADE EXTEND (n = 1116) included patients (≥12 years) with moderate-to-severe AD who completed abrocitinib (200/100 mg) or placebo treatment in JADE MONO-1, JADE MONO-2, or JADE COMPARE study and received abrocitinib (200/100 mg) with or without topical therapy.
Disclosures: This study was funded by Pfizer Inc. Some authors declared receiving grants, fees, etc., from and serving as consultants, speakers, advisors, or investigators for Pfizer Inc. and others. Five authors declared being employees or shareholders of Pfizer Inc.
Source: Reich K et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023 (Jun 19). Doi: 10.1111/jdv.19280
Key clinical point: Long-term abrocitinib monotherapy or with medicated topical therapy demonstrates a manageable safety profile and significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults and adolescents.
Major finding: At week 48, in the 200 and 100 mg abrocitinib groups, Eczema Area and Severity Index-75 (EASI 75) responses and ≥4-point improvements in Peak Pruritus Numerical Rating Scale (PP-NRS) scores were achieved by 81.7% and 66.8% (EASI 75), and 67.9% and 51.1% (PP-NRS) of patients, respectively; serious treatment-emergent adverse event rates were 7.1% and 4.7% (200 mg vs 100 mg), respectively.
Study details: This phase 3 long-term extension study JADE EXTEND (n = 1116) included patients (≥12 years) with moderate-to-severe AD who completed abrocitinib (200/100 mg) or placebo treatment in JADE MONO-1, JADE MONO-2, or JADE COMPARE study and received abrocitinib (200/100 mg) with or without topical therapy.
Disclosures: This study was funded by Pfizer Inc. Some authors declared receiving grants, fees, etc., from and serving as consultants, speakers, advisors, or investigators for Pfizer Inc. and others. Five authors declared being employees or shareholders of Pfizer Inc.
Source: Reich K et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023 (Jun 19). Doi: 10.1111/jdv.19280
Key clinical point: Long-term abrocitinib monotherapy or with medicated topical therapy demonstrates a manageable safety profile and significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults and adolescents.
Major finding: At week 48, in the 200 and 100 mg abrocitinib groups, Eczema Area and Severity Index-75 (EASI 75) responses and ≥4-point improvements in Peak Pruritus Numerical Rating Scale (PP-NRS) scores were achieved by 81.7% and 66.8% (EASI 75), and 67.9% and 51.1% (PP-NRS) of patients, respectively; serious treatment-emergent adverse event rates were 7.1% and 4.7% (200 mg vs 100 mg), respectively.
Study details: This phase 3 long-term extension study JADE EXTEND (n = 1116) included patients (≥12 years) with moderate-to-severe AD who completed abrocitinib (200/100 mg) or placebo treatment in JADE MONO-1, JADE MONO-2, or JADE COMPARE study and received abrocitinib (200/100 mg) with or without topical therapy.
Disclosures: This study was funded by Pfizer Inc. Some authors declared receiving grants, fees, etc., from and serving as consultants, speakers, advisors, or investigators for Pfizer Inc. and others. Five authors declared being employees or shareholders of Pfizer Inc.
Source: Reich K et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023 (Jun 19). Doi: 10.1111/jdv.19280